Virtual Library

Start Your Search

Fumiyoshi Ohyanagi



Author of

  • +

    P2.01 - Advanced NSCLC (ID 159)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 2
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.01-76 - Bone Metastasis and Pleural Dissemination as a Potential Marker for Predicting of T790M Mutation in Advanced Non-Small Cell Lung Cancer Patients (Now Available) (ID 508)

      10:15 - 18:15  |  Presenting Author(s): Fumiyoshi Ohyanagi

      • Abstract
      • Slides

      Background

      Acquired resistance in epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)-patients after tyrosine kinase inhibitor (TKI)-treatment is a major clinical problem. In the majority of these patients, the T790M-mutation is detected at time of acquired TKI-resistance. However, it is less clear if the location of metastatic site may influence the ability to identify T790M mutation in NSCLC patients.

      Method

      We retrospectively screened patients with NSCLC harboring EGFR mutations with progressive disease who were rebiopsied between January 2016 and December 2018. EGFR T790M mutation status after EGFR-TKIs failure was assessed using liquid biopsy or tissue rebiopsy sample. Clinical factors influencing T790M status were evaluated by univariate and multivariate analysis.

      Result

      Among 39 rebiopsied patients for whom EGFR mutation status was available, 21 (53.8%) had T790M mutations. Patient characteristics at rebiopsy were not significantly different between T790M-positive and -negative groups, except for bone metastasis. Total duration of EGFR-TKI treatment before rebiopsy, EGFR-TKI treatment history immediately before rebiopsy, progression-free survival after initial TKI treatment, and rebiopsy site (other than fluid samples) significantly influenced T790M status. The incidence of T790M mutation was shown by multivariate analysis to be significantly higher in patients with bone metastasis and pleural dissemination (odds ratio, 26.4; 95% confidence interval (CI), 3.80-184 and odds ratio, 12.1; 95% CI, 1.57-92.4, respectively).

      Conclusion

      Bone metastasis and pleural dissemination may represent useful predictive markers for T790M detection. In patients with these clinical factors, rebiopsies may be more recommended to detect T790M mutation.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P2.01-95 - Updated Data of KRSG 1302 Study: Nedaplatin and Nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer (Now Available) (ID 136)

      10:15 - 18:15  |  Presenting Author(s): Fumiyoshi Ohyanagi

      • Abstract
      • Slides

      Background

      Background: Nedaplatin (N) and nab-paclitaxel (nab-P) are efficacious for the treatment of non-small cell lung cancer, especially advanced squamous cell lung cancer. Although a combination of N and nab-P is expected to result in the treatment of squamous cell lung cancer, no sufficient and reliable data have been reported yet.

      Method

      Patients and methods: The inclusion criteria were no prior chemotherapy; stage IIIB or stage IV squamous cell lung cancer; a performance status (PS) of 0–1; 75 > patients’ age > 20 years; and adequate major organ function. Patients received escalating doses of nab-P under a fixed dose of N (100 mg/m2, 1st day) every 3 weeks in phase I. The initial dose of nab-P was 100 mg/m2 on the 1st and 8th day (level 1), and the next dose was 100 mg/m2 on the 1st, 8th, and 15th day (level 2). In phase II, the patients received the recommended dose of N/nab-P. The primary endpoint was tumor response, which was measured according to the revised version of response evaluation criteria in solid tumors.

      Result

      Results: In this study, 5 patients were enrolled in the phase I. Three patients in level 1 experienced no dose-limiting toxicities (DLTs); whereas, 2 patients in level 2 experienced DLTs. Therefore, level 1 was named the recommended dose. In addition, 23 patients were enrolled in phase II. Three and 23 patients in level 1 and phase II were evaluated, respectively. However, among them, 2 of 26 patients were not assessed due to pneumonia, and 1 of 26 patients was excluded from analysis due to patients’ refusal. Partial response, stable disease, and progressive disease were noted in 21, 0, and 2 patients, respectively, yielding a response rate of 91.3% [95% confidence interval (CI): 72.0–98.9]. The median progression-free survival (PFS) was 223 days (95%CI: 144–330), and the median overall survival (OS) was 358 days (95% CI: 255–950). The 1- and 2-year PFS rate were 17.8% and 12.0%. The 1- and 2-year OS rate were 50.0% and 43.8%, respectively. The grade 3 and grade 4 toxicities were manageable and there was no treatment-related death. These data were published in 2018 ESMO. We will report updated efficacy and safety of N/nab-P in KRSG 1302 study.

      Conclusion

      Conclusions: A combination of N (100 mg/m2, 1st day) with nab-P (100 mg/m2, 1st and 8th day) every 3 weeks demonstrated an effective therapeutic approach. Therefore, N/nab-P administration is to be safe and efficacious for patients with advanced squamous cell lung cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.